AIM
AIM ImmunoTech Inc. AMEX$0.52
Pre-mkt
$0.52
-0.04%
Mkt Cap $1.8M
52w Low $0.48
0.2% of range
52w High $19.74
50d MA $0.69
200d MA $1.84
P/E (TTM)
-0.1x
EV/EBITDA
-0.6x
P/B
—
Debt/Equity
-0.5x
ROE
142.7%
P/FCF
-0.2x
RSI (14)
—
ATR (14)
—
Beta
1.36
50d MA
$0.69
200d MA
$1.84
Avg Volume
4.7M
About
AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. Its flagship products are Ampligen (rintatolimod), a drug of large macromolecular double-stranded ribonucleic acid molecules to treat chronic fatigue syndrome; and Alferon N Injection (Interf…
Recent Earnings
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | 1M% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 27, 2026 | AMC | -0.94 | -0.44 | +53.2% | 0.70 | +2.0% | -21.3% | -16.4% | -21.4% | -15.0% | -15.6% | -26.3% | — |
| Nov 17, 2025 | AMC | -0.97 | -1.57 | -61.0% | 1.44 | +0.7% | -7.6% | -7.6% | -9.7% | -4.9% | -6.2% | -6.9% | — |
| Aug 14, 2025 | AMC | -8.00 | -3.68 | +54.0% | 2.42 | +0.0% | +2.9% | -8.3% | -2.5% | -3.3% | +4.5% | -0.8% | — |
| May 15, 2025 | AMC | -8.00 | -5.00 | +37.5% | 8.47 | +0.0% | -11.1% | +0.0% | +0.0% | +0.0% | +0.0% | +5.4% | — |
| Mar 27, 2025 | AMC | -9.00 | -10.00 | -11.1% | 12.23 | +0.0% | -7.7% | -7.7% | +0.0% | -7.7% | -7.7% | -53.8% | — |
| Nov 14, 2024 | AMC | -10.00 | -6.00 | +40.0% | 23.52 | -4.0% | -12.0% | -8.0% | -28.0% | -20.0% | -16.0% | -16.0% | — |
| Aug 14, 2024 | AMC | -0.12 | -3.00 | -2400.0% | 25.40 | +0.0% | +7.4% | +11.1% | +14.8% | +33.3% | +44.4% | +11.1% | — |
| May 16, 2024 | AMC | -0.11 | -12.00 | -9999.0% | 36.69 | +7.7% | +2.6% | +5.1% | +5.1% | +5.1% | +2.6% | +10.3% | — |
| Mar 29, 2024 | AMC | -0.15 | -26.00 | -9999.0% | — | — | — | — | — | — | — | — | — |
| Nov 14, 2023 | AMC | -0.11 | -16.00 | -9999.0% | 42.34 | +0.0% | +4.4% | +4.4% | +0.0% | -8.9% | -11.1% | +17.8% | — |
Recent Analyst Ratings
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 10 | Ascendiant Capital | Maintains | Buy → Buy | — | $0.52 | $0.53 | +2.3% | +1.2% | +2.5% | +11.7% | +5.3% | +8.5% |
| Dec 8 | Ascendiant Capital | Maintains | Buy → Buy | — | $1.38 | $1.39 | +0.7% | +10.1% | +8.0% | +5.1% | +5.1% | -0.7% |
| Oct 3 | Ascendiant Capital | Maintains | Buy → Buy | — | $2.49 | $2.55 | +2.4% | -0.4% | +1.2% | -0.8% | -2.8% | -1.6% |
| Dec 10 | Ascendiant Capital | Maintains | Buy → Buy | — | $20.70 | $21.64 | +4.5% | +0.0% | -4.5% | -4.5% | +0.0% | -4.5% |
| Oct 22 | Maxim Group | Maintains | Buy → Buy | — | $24.46 | $25.40 | +3.8% | +3.8% | +0.0% | +0.0% | +3.8% | +3.8% |
| Sep 3 | Ascendiant Capital | Maintains | Buy → Buy | — | $31.99 | $31.99 | +0.0% | +2.9% | +0.0% | -2.9% | -2.9% | -2.9% |
| Oct 10 | Maxim Group | Upgrade | Hold → Buy | — | $53.63 | $64.92 | +21.1% | +5.3% | +3.5% | +1.8% | -3.5% | +3.5% |
| Aug 22 | Maxim Group | Downgrade | Buy → Hold | — | $180.63 | $180.63 | +0.0% | +0.0% | +0.5% | -2.6% | -2.6% | -3.1% |
| Jun 14 | Maxim Group | Maintains | Buy → Buy | — | $503.31 | $518.36 | +3.0% | -5.0% | -10.3% | -20.2% | -24.9% | -24.7% |
| Jan 21 | Chardan Capital | Maintains | Buy → Buy | — | $20365.75 | $24836.29 | +22.0% | +9.8% | +12.2% | +34.1% | +24.4% | +17.1% |
Recent Filings
8-K · 1.01
!! High
Unknown — 8-K 1.01: Distribution Agreement
AIM can raise up to $3.0 million through Maxim Group LLC, providing capital flexibility without debt while diluting existing shareholders unless proceeds fund accretive growth.
Apr 10
8-K · 8.01
!! High
AIM ImmunoTech Inc. -- 8-K 8.01: Material Event / Announcement
AIM ImmunoTech completed its rights offering, allowing existing shareholders to purchase additional shares at a predetermined price to raise capital.
Mar 6
8-K · 8.01
!! High
AIM ImmunoTech Inc. -- 8-K 8.01: Material Event / Announcement
AIM ImmunoTech is conducting a Phase I/II trial combining Durvalumab and Rintatolimod for pancreatic cancer, with interim results potentially validating the company's immunotherapy approach for this difficult-to-treat indication.
Feb 5
Data updated apr 24, 2026 4:51pm
· Source: massive.com